Reversing Therapy Resistance With Epigenetic-Immune Modification

NCT02395627 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

38

Enrollment

OTHER

Sponsor class

Stopped Insufficient efficacy in an unselected patient population

Conditions

Breast Neoplasms

Interventions

DRUG: Tamoxifen
DRUG: Vorinostat
DRUG: Pembrolizumab

Sponsor

University of California, San Francisco

Collaborators

[object Object]
[object Object]